Phospho-Cyclin B1 (Ser116) Antibody



Orders: 877-616-CELL (2355) orders@cellsignal.com

Web: info@cellsignal.com

cellsignal.com

877-678-TECH (8324)

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

Support:

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity:	Sensitivity: Endogenous	MW (kDa): 55	Source/Isotype: Rabbit	UniProt ID: #P14635	Entrez-Gene Id: 891
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		Phospho-Cyclin B1 (Ser116) recognizes endogenous levels of cyclin B1 protein only when phosphorylated at Ser116.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser116 of human cyclin B1 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		through the cell cycle cdc2/cdk1 at the G2/N the regulatory subun remains in the inactiv (CAK) (1,2) and dephosphorylation sites (CRS) domain and are checkpoint, promotin phosphorylate Ser128 Ser133 and possibly anaphase-promoting	. The entry of all eu of transition. This ac it, cyclin B1, to cdc2 te state until phospl isphorylation of cdc is (Ser116, 126, 128, thought to regulat g nuclear accumula and Ser128, polo- at Ser147 (6,10). At t complex (APC), allo	ate specific cyclin-depen karyotic cells into mitosi tivation is a multi-step p /cdk1 to form the mitosi norylation of cdc2/cdk1 a 2/cdk1 at Thr14/Tyr15 b 133, and 147) are locate e the translocation of cy ition and initiation of mi ike kinase 1 (PLK1) phos he end of mitosis, cyclin wing for cell cycle progr breast, prostate, and no	is is regulated by actorocess that begins is-promoting factor at Thr161 by cdk acty cdc25C (3-5). Five d in the cytoplasmic iclin B1 to the nucle tosis (6-9). While Misphorylates cyclin B is targeted for clession (11). Researce	tivation of with the binding of (MPF). MPF tivating kinase cyclin B1 c retention signal us at the G2/M PF itself can 1 preferentially at degradation by the
Background References		shown that cyclin B1 is overexpressed in breast, prostate, and non-small cell lung cancers (12-14). 1. Lorca, T. et al. (1992) EMBO J 11, 2381-90. 2. Harper, J.W. and Elledge, S.J. (1998) Genes Dev 12, 285-9. 3. Norbury, C. et al. (1991) EMBO J 10, 3321-9. 4. McGowan, C.H. and Russell, P. (1993) EMBO J 12, 75-85. 5. Atherton-Fessler, S. et al. (1994) Mol Biol Cell 5, 989-1001. 6. Toyoshima-Morimoto, F. et al. (2001) Nature 410, 215-20. 7. Li, J. et al. (1997) Proc Natl Acad Sci U S A 94, 502-7. 8. Takizawa, C.G. and Morgan, D.O. (2000) Curr Opin Cell Biol 12, 658-65. 9. Santos, S.D. et al. (2012) Cell 149, 1500-13. 10. Jackman, M. et al. (2003) Nat Cell Biol 5, 143-8. 11. Gong, D. and Ferrell, J.E. (2010) Mol Biol Cell 21, 3149-61. 12. Mashal, R.D. et al. (1996) Cancer Res 56, 4159-63. 13. Kawamoto, H. et al. (1997) Am J Pathol 150, 15-23. 14. Soria, J.C. et al. (2000) Cancer Res 60, 4000-4.				

Species Reactivity Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X

TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.